Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2013

01-04-2013 | Research Article

A retrospective analysis of drug-related problems documented in a national database

Authors: Tommy Westerlund, Ulrika Gelin, Elisabeth Pettersson, Fredrik Skärlund, Kajsa Wågström, Carina Ringbom

Published in: International Journal of Clinical Pharmacy | Issue 2/2013

Login to get access

Abstract

Background Numerous patients are subject to drug-related problems (DRPs) every day, resulting in sub-optimal therapy, suffering and decreased quality of life, as well as in high societal health care costs. Classifying DRPs is important for the development of counselling skills and for pharmaceutical care practice and research, including assessments of the value of pharmacists’ clinical interventions. Pharmacy practitioners have also reported to become more attentive to patients’ drug-related needs, when requested to document their clinical interventions. Several studies have been conducted on DRPs, but there is still a need for a more thorough knowledge about their nature and the reasons for their occurrence. To examine DRP characteristics and causes by retrospectively analysing data and patient case histories, as documented by pharmacy practitioners in the Swedish national DRP database. Setting Community pharmacy based patient documentation, entered into the Swedish national DRP database. Method Documented DRPs, clinical interventions and patient data were retrospectively examined and analysed. Particular attention was paid to case history reports in free text fields. Only reports containing adequate information for analysis and actual, correctly categorised DRPs were included. Main outcome measure Subdivided DRP characteristics and causes. Results Both similarities and differences between DRP subclasses of prescription patients (n = 5,571) and OTC drug consumers (n = 2,894) were observed. Most DRP categories could be subdivided into at least three subclasses, according to their characteristics. Causes of DRPs could be extracted from free text field reports in four prescription DRP categories and three OTC DRP categories. Uncertainty about the aim of the drug was commonly characterised by a lack of knowledge about the indication in prescription patients and in an inappropriate drug selection in OTC drug consumers. A switch from a brand-name drug to a generic drug or from one generic to another was the cause in half of the therapy failures, which in turn was a frequent reason for overuse of drug. Conclusion The study demonstrates the multi-facetted drug-related problems in patients and confirms the importance of attention by pharmacy practitioners for the detection of and intervention for DRPs.
Literature
1.
go back to reference van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother. 2004;38:859–67.PubMedCrossRef van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother. 2004;38:859–67.PubMedCrossRef
2.
go back to reference Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: meta-analysis of prospective studies. JAMA. 1998;279:1200–5.PubMedCrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: meta-analysis of prospective studies. JAMA. 1998;279:1200–5.PubMedCrossRef
3.
go back to reference Pouyanne P, Haramburu F, Imbs JL. Be′gaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. Br Med J. 2000;320:1036.CrossRef Pouyanne P, Haramburu F, Imbs JL. Be′gaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. Br Med J. 2000;320:1036.CrossRef
4.
go back to reference Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36:1238–48.PubMedCrossRef Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36:1238–48.PubMedCrossRef
5.
go back to reference Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a metaanalysis of observational studies. Pharm World Sci. 2002;24:46–54.PubMedCrossRef Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a metaanalysis of observational studies. Pharm World Sci. 2002;24:46–54.PubMedCrossRef
6.
go back to reference Fryckstedt J, Asker-Hagelberg C. Läkemedelsrelaterade problem vanliga på medicinakuten [Drug-related problems common at the medical emergency ward]. Swedish Läkartidningen. 2008;105:894–8. Fryckstedt J, Asker-Hagelberg C. Läkemedelsrelaterade problem vanliga på medicinakuten [Drug-related problems common at the medical emergency ward]. Swedish Läkartidningen. 2008;105:894–8.
7.
go back to reference McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.PubMedCrossRef McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.PubMedCrossRef
8.
go back to reference Lobo BL, Reinke DW, Swearingen LL. Medication-related problems: a common cause of hospital readmission. AACP and ESCP International Congress on Clinical Pharmacy. Documenting the value of clinical pharmacy services, Orlando, 1999; Poster 200E. Pharmacotherapy 1999; 19:510. Lobo BL, Reinke DW, Swearingen LL. Medication-related problems: a common cause of hospital readmission. AACP and ESCP International Congress on Clinical Pharmacy. Documenting the value of clinical pharmacy services, Orlando, 1999; Poster 200E. Pharmacotherapy 1999; 19:510.
9.
go back to reference Smith DL. The effect of patient non-compliance on health care costs. Med Interface 1993; 6(4):74–76, 78, 84. Smith DL. The effect of patient non-compliance on health care costs. Med Interface 1993; 6(4):74–76, 78, 84.
10.
go back to reference Guignard AP, Couray-Targe S, Colin C, Chamba G. Economic impact of pharmacists’ interventions with nonsteroidal anti-inflammatory drugs. Ann Pharmacother. 2003;37:332–8.PubMedCrossRef Guignard AP, Couray-Targe S, Colin C, Chamba G. Economic impact of pharmacists’ interventions with nonsteroidal anti-inflammatory drugs. Ann Pharmacother. 2003;37:332–8.PubMedCrossRef
11.
go back to reference Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty- five years of experience. Curr Pharm Des. 2004;10:3987–4001.PubMedCrossRef Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty- five years of experience. Curr Pharm Des. 2004;10:3987–4001.PubMedCrossRef
12.
go back to reference Benrimoj SI, Langford JH, Berry G, Collins D, Lauchlan R, Stewart K, et al. Economic impact of increased clinical intervention rates in community pharmacy. A randomized trial of the effect of education and a professional allowance. Pharmacoeconomics. 2000;18:459–68.PubMedCrossRef Benrimoj SI, Langford JH, Berry G, Collins D, Lauchlan R, Stewart K, et al. Economic impact of increased clinical intervention rates in community pharmacy. A randomized trial of the effect of education and a professional allowance. Pharmacoeconomics. 2000;18:459–68.PubMedCrossRef
13.
go back to reference Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34:319–27.PubMedCrossRef Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34:319–27.PubMedCrossRef
14.
go back to reference Westerlund LOT, Handl WHA, Marklund BRG, Allebeck P. Pharmacy practitioners’ views on computerized documentation of drug-related problems. Ann Pharmacother. 2003;37:354–60.PubMedCrossRef Westerlund LOT, Handl WHA, Marklund BRG, Allebeck P. Pharmacy practitioners’ views on computerized documentation of drug-related problems. Ann Pharmacother. 2003;37:354–60.PubMedCrossRef
15.
go back to reference Westerlund T. Kunders/patienters läkemedelsrelaterade problem [Customers’/patients’ drug-related problems] in Från förskrivning till användning—Farmacevtens roll för en bättre läkemedelsanvändning [From prescribing to use—the pharmacist’s role for an improved drug use], p.133. Swedish. Carlsten A, Castensson S (editors). ISBN 978-91- 976510-8-0. Apotekarsocieten, Stockholm, 2011. Westerlund T. Kunders/patienters läkemedelsrelaterade problem [Customers’/patients’ drug-related problems] in Från förskrivning till användning—Farmacevtens roll för en bättre läkemedelsanvändning [From prescribing to use—the pharmacist’s role for an improved drug use], p.133. Swedish. Carlsten A, Castensson S (editors). ISBN 978-91- 976510-8-0. Apotekarsocieten, Stockholm, 2011.
16.
go back to reference Apoteket AB. Statistics. Stockholm: National DRP database; 2010. Apoteket AB. Statistics. Stockholm: National DRP database; 2010.
18.
go back to reference Westerlund T, Almarsdóttir AB, Melander A. Drug-related problems and pharmacy interventions in community practice. Int J Pharm Pract. 1999;7:40–50.CrossRef Westerlund T, Almarsdóttir AB, Melander A. Drug-related problems and pharmacy interventions in community practice. Int J Pharm Pract. 1999;7:40–50.CrossRef
19.
go back to reference Ax F, Brånstad J-O, Westerlund T. Pharmacy counselling models—a means to improve patient drug use. J Clin Pharm Ther. 2010;35:439–51.PubMed Ax F, Brånstad J-O, Westerlund T. Pharmacy counselling models—a means to improve patient drug use. J Clin Pharm Ther. 2010;35:439–51.PubMed
20.
go back to reference Hämmerlein A, Griese N, Schulz M. Survey of drug-related problems identified by community pharmacies. Ann Pharmacother. 2007;41:1825–32.PubMedCrossRef Hämmerlein A, Griese N, Schulz M. Survey of drug-related problems identified by community pharmacies. Ann Pharmacother. 2007;41:1825–32.PubMedCrossRef
21.
go back to reference Williams M, Peterson GM, Tenni PC, Bindoff IK, Curtain C, Hughes J, et al. Drug-related problems detected in Australian community pharmacies: the PROMISe Trial. Ann Pharmacother. 2011;45:1067–76.PubMedCrossRef Williams M, Peterson GM, Tenni PC, Bindoff IK, Curtain C, Hughes J, et al. Drug-related problems detected in Australian community pharmacies: the PROMISe Trial. Ann Pharmacother. 2011;45:1067–76.PubMedCrossRef
23.
go back to reference Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef
24.
go back to reference Krähenbühl JM, kremer B, Guignard B, Bugnon O. Practical evaluation of the drug- related problem management process in Swiss community pharmacies. Pharm World Sci. 2008;30:777–86.PubMedCrossRef Krähenbühl JM, kremer B, Guignard B, Bugnon O. Practical evaluation of the drug- related problem management process in Swiss community pharmacies. Pharm World Sci. 2008;30:777–86.PubMedCrossRef
25.
go back to reference Eickhoff C, Hämmerlein A, Griese N, Schulz M. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012;21:254–60.PubMedCrossRef Eickhoff C, Hämmerlein A, Griese N, Schulz M. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012;21:254–60.PubMedCrossRef
26.
go back to reference Al-Jazairi AS, Bhareth S, Eqtefan IS, Al-Suwayeh SA. Brand and generic medications: are they interchangeable? Ann Saudi Med. 2008;28(1):33–41. Review.PubMedCrossRef Al-Jazairi AS, Bhareth S, Eqtefan IS, Al-Suwayeh SA. Brand and generic medications: are they interchangeable? Ann Saudi Med. 2008;28(1):33–41. Review.PubMedCrossRef
27.
go back to reference Heller FR, Dupont AG. Generics: need for clinical concern? Acta Clin Belg. 2009;64:415–22.PubMed Heller FR, Dupont AG. Generics: need for clinical concern? Acta Clin Belg. 2009;64:415–22.PubMed
28.
go back to reference Hellström J, Rudholm N. Side effects of generic competition? Eur J Health Econ. 2004;5(3):203–8.PubMedCrossRef Hellström J, Rudholm N. Side effects of generic competition? Eur J Health Econ. 2004;5(3):203–8.PubMedCrossRef
29.
go back to reference Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320–34.PubMedCrossRef Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320–34.PubMedCrossRef
30.
go back to reference Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol. 2010;70(3):335–41.PubMedCrossRef Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol. 2010;70(3):335–41.PubMedCrossRef
Metadata
Title
A retrospective analysis of drug-related problems documented in a national database
Authors
Tommy Westerlund
Ulrika Gelin
Elisabeth Pettersson
Fredrik Skärlund
Kajsa Wågström
Carina Ringbom
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9724-1

Other articles of this Issue 2/2013

International Journal of Clinical Pharmacy 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.